Barr files Seasonique
Executive Summary
Barr files NDA for 91-day extended regimen oral contraceptive Seasonique (84 tablets of 0.15 mg levonorgestrel/0.03 ethinyl estradiol; seven tablets of 0.01 mg ethinyl estradiol) in early October, the company said on its quarterly earnings call Nov. 4. Barr already markets Seasonale (84 tablets 0.15 mg levonorgestrel/0.03 ethinyl estradiol; seven inert tablets). "We have chosen the name Seasonique to leverage the very favorable reception our Seasonale product has received in the marketplace and to connote that it is part of a family of products in this area," CEO Bruce Downey said. Seasonique was previously referred to as DP3; the company is also developing lower-dose Seasonale Ultra-Lo...
|
Barr files NDA for 91-day extended regimen oral contraceptive Seasonique (84 tablets of 0.15 mg levonorgestrel/0.03 ethinyl estradiol; seven tablets of 0.01 mg ethinyl estradiol) in early October, the company said on its quarterly earnings call Nov. 4. Barr already markets Seasonale (84 tablets 0.15 mg levonorgestrel/0.03 ethinyl estradiol; seven inert tablets). "We have chosen the name Seasonique to leverage the very favorable reception our Seasonale product has received in the marketplace and to connote that it is part of a family of products in this area," CEO Bruce Downey said. Seasonique was previously referred to as DP3; the company is also developing lower-dose Seasonale Ultra-Lo .... |